NervGen Pharma (NASDAQ:NGEN) Releases Earnings Results, Beats Estimates By $999.07 EPS

NervGen Pharma (NASDAQ:NGEN) released its earnings results on Friday. The company reported $999.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $999.07, reports.

NervGen Pharma Trading Down 3.8%

NASDAQ NGEN traded down $0.14 on Friday, reaching $3.57. The company had a trading volume of 407,740 shares, compared to its average volume of 168,767. NervGen Pharma has a 12 month low of $1.50 and a 12 month high of $6.30.

Analysts Set New Price Targets

A number of research analysts recently weighed in on NGEN shares. Wall Street Zen cut shares of NervGen Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday. HC Wainwright upgraded shares of NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Weiss Ratings started coverage on shares of NervGen Pharma in a research note on Friday, April 24th. They set a “sell (d-)” rating on the stock. Zacks Research upgraded shares of NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Finally, Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, NervGen Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.